DENVER, Nov. 26, 2012 /PRNewswire/ -- FusionPharm,
Inc. (OTC: FSPM), the developer of the patent pending PharmPods(TM)
hydroponic cultivation system, today announced that it has signed a
licensing agreement with Colorado
based Meadpoint Venture Partners to market the PharmPod High
Intensity line of controlled environment agriculture containers.
PharmPod High Intensity containers utilize High Intensity Discharge
(HID) and/or High Pressure Sodium (HPS) lighting systems to achieve
outstanding results with fruiting and flowering plants.
"We are excited to partner with Meadpoint and expect big things
from them in the flowering and fruiting sectors in the next 18
months," explained FusionPharm CEO Scott
Dittman. "This will allow us to maintain our focus and
to dedicate our resources to the natural foods marketplace and
completion of our PharmPlex product development while Meadpoint
markets the PharmPod High Intensity containers into the burgeoning
cannabis marketplace."
An initial order for 8 PharmPod High Intensity containers was
received from Meadpoint on November
19th with minimum purchase quantities of 50
containers in both 2013 and 2014.
About FusionPharm, Inc.
FusionPharm, Inc. was organized to capitalize on opportunities
present in the rapidly growing the $26
billion organic food and specialty herb industries.
FusionPharm's primary focus is the development and deployment of
the patent pending PharmPods(TM) advanced hydroponic cultivation
systems. PharmPods are constructed from standard ISO steel shipping
containers that are repurposed for use in indoor plant cultivation.
Using advanced LED lighting technology, cutting edge growing media
and proprietary cultivation techniques, a single PharmPod is
capable of growing more produce than one full acre of traditional
agriculture in less than half the time using 90% less water than
traditional agriculture and no harmful pesticides or
herbicides.
NOTES ABOUT FORWARD-LOOKING STATEMENTS: Except for any
historical information contained herein, the matters discussed in
this press release contain forward-looking statements that involve
risks and uncertainties, including those described in the Company's
Securities and Exchange Commission reports and filings. Certain
statements contained in this release that are not historical facts
constitute forward-looking statements, within the meaning of the
Private Securities Litigation Reform Act of 1995, and are intended
to be covered by the safe harbors created by that Act. Reliance
should not be placed on forward-looking statements because they
involve unknown risks, uncertainties and other factors, which may
cause actual results, performance or achievements to differ
materially from those expressed or implied. Forward-looking
statements may be identified by words such as estimates,
anticipates, projects, plans, expects, intends, believes, should
and similar expressions and by the context in which they are used.
Such statements are based upon current expectations of the Company
and speak only as of the date made. The Company undertakes no
obligation to update any forward-looking statements to reflect
events or circumstances after the date on which they are made.
Contact: FusionPharm, Inc.
info@fusionpharminc.com
SOURCE FusionPharm, Inc.